Testing effectiveness (Phase 2)UnknownNCT02452697
What this trial is testing
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
Who this might be right for
Myeloid MalignanciesLymphoid Malignancies
Cristina Gasparetto 36